Biohaven (BHVN) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $2.19B and a free-cash-flow yield of -39.2%. Nama's AI scorecard rates it Sell, 2.5 out of 10. On 12-month momentum it ranks in the rising band of its market.
AI scorecard
Sell · 2.5/10
Clearly negative, short of the bottom band. As of Nov 7, 2026.
Momentum
Rising · +39.3% over 12 months ex. last
Second-best fifth of its market on the past year's move.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-90.5%
How far the last close sits under the highest price of the past five years.
Market cap
$2.19B
Trailing P/E
—
Price / book
181.0
Price / sales
—
FCF yield
-39.2%
Dividend yield
—
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
3.2
Exchange
NYSE
Sector
Healthcare
Industry
Biotechnology
BHVN earnings
Next report: Mar 1, 2027 (Q4 2026, EPS estimate $0.60).
Beat the EPS estimate in 2 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Oct 29, 2026
-$0.73
$0.16
-556.2%
$0
Q2 2026
Aug 10, 2026
-$0.78
-$0.61
-27.9%
$0
Q1 2026
May 4, 2026
-$0.69
-$0.76
+9.2%
$0
Q4 2025
Mar 2, 2026
-$0.90
-$0.96
+6.2%
$0
BHVN analyst price target
Median target $23.00 from 15 analysts, ranging $9.00 – $48.00.
Nama's AI scorecard currently rates Biohaven Sell (2.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does BHVN report earnings?
Biohaven's next scheduled report is on Mar 1, 2027. Analysts expect EPS of $0.60.
What is the BHVN price target?
The median analyst price target from 15 analysts is $23.00, with a range of $9.00 – $48.00.
Is BHVN Shariah compliant?
Nama's AAOIFI-style screen reads Biohaven as Can't Tell. A figure the screen needs is missing, so it can't tell.